Disease, destination, dose and delivery aspects of ciclosporin: the state of the art

Drug Discovery Today

Volumn 11, Issue 17-18, 2006, Pages 846-854

  Italia, Jagdish L ^a   Bhardwaj, Vivekanand ^a   Ravi Kumar, M N V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LIPOSOME; NANOPARTICLE;

ANAPHYLAXIS; ATAXIA; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CEREBRAL BLINDNESS; CLINICAL TRIAL; COMA; CONFUSION; CONVULSION; DEPRESSION; DRUG EFFICACY; DRUG SOLUBILITY; EMULSION; FLUSHING; GINGIVA DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPERURICEMIA; INFECTION; LETHARGY; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MEMBRANE TRANSPORT; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; PARALYSIS; REVIEW; SPASTICITY; THROMBOCYTOSIS; THROMBOEMBOLISM; TREMOR;

ANIMALS; CYCLOSPORINE; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 33747795904     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.07.015     Document Type: Review

References (73)

1. Stahelin H.F. The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia 52 (1996) 5-13
2. Wenger R.M. Total synthesis of 'cyclosporin A' and 'cyclosporin H', two fungal metabolites isolated from species Tolypocladium Inflatum Gams. Helv. Chim. Acta 67 (1984) 503-515
3. Tayar N.E. Solvent dependent conformation and hydrogen-bonding capacity of cyclosporine A: Evident from partition coefficients and molecular dynamics simulations. J. Med. Chem. 36 (1993) 3757-3764
4. Hamel A.R., et al. Cyclosporin A prodrugs: design, synthesis and biophysical properties. J. Pept. Res. 63 (2004) 147-154
5. Lallemand F., et al. A water-soluble prodrug of cyclosporine A for ocular application: a stability study. Eur. J. Pharm. Sci. 26 (2005) 124-129
6. Schumacher A., and Nordheim A. Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression. Clin. Investig. 70 (1992) 773-779
7. Faulds D., et al. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45 (1993) 953-1040
8. Busauschina A., et al. Cyclosporine nephrotoxicity. Transplant. Proc. 36 (2004) 229S-233S
9. Rezzani R., et al. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int. Immunopharmacol. 5 (2005) 1397-1405
10. Mun K.C. Effect of Epigallocatechin Gallate on Renal Function in Cyclosporine- Induced Nephrotoxicity. Transplant. Proc. 36 (2004) 2133-2134
11. Bistrup C., et al. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol. Dial. Transplant. 16 (2001) 373-377
12. Tsunoda S.M., et al. Red wine decreases cyclosporine bioavailability. Clin. Pharmacol. Ther. 70 (2001) 462-467
13. Kahan B.D. Considerations concerning generic formulations of immunosuppressive drugs. Transplant. Proc. 31 (1999) 1635-1641
14. Jorga A., et al. Therapeutic drug monitoring of cyclosporine. Transplant. Proc. 36 (2004) 396S-403S
15. Sindhi R., et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 69 (2000) 432-436
16. Halloran P.F., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68 (1999) 1356-1361
17. Nashan B., et al. Use of Neoral C2 monitoring: a European consensus. Transpl. Int. 18 (2005) 768-778
18. Mahalati K., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 68 (1999) 55-62
19. Mithani S.D., et al. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13 (1996) 163-167
20. Wu C.-Y., et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Therap. 58 (1995) 492-497
21. Varma M.V.S., et al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metab. 5 (2004) 375-388
22. Fricker G., et al. Relevance of p-glycoprotein for entral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118 (1996) 1841-1847
23. Kovarik J.M., et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83 (1994) 444-446
24. Lee E.J., et al. Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int. J. Pharm. 218 (2001) 125-131
25. Francis M.F., et al. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells. Pharm. Res. 22 (2005) 209-219
26. Desai M.P., et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14 (1997) 1568-1573
27. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 249 (2002) 101-108
28. Dai J., et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280 (2004) 229-240
29. Guzman M., et al. Formation and characterization of cyclosporine-loaded nanoparticles. J. Pharm. Sci. 82 (1993) 498-502
30. Varela M.C., et al. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12 (2001) 471-478
31. Gref R., et al. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51 (2001) 111-118
32. Bekerman T., et al. Cyclosporin nanoparticulate lipospheres for oral administration. J. Pharm. Sci. 93 (2004) 1264-1270
33. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Pharmacother. 28 (1994) 511-514
34. Volcheck G.W., and Van Dellen R.G. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann. Allergy Asthma Immunol. 80 (1998) 159-163
35. Venkataramanan R., et al. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am. J. Hosp. Pharm. 43 (1986) 2800-2802
36. Pearson S.D., and Trissel L.A. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am. J. Hosp. Pharm. 50 (1993) 1405-1409
37. Smeesters C., et al. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity. Can. J. Surg. 31 (1988) 34-36
38. Akbarieh M., et al. Reduced kallikrein excretion by liposome-encapsulated cyclosporin in the rat. J. Pharm. Pharmacol. 45 (1993) 146-148
39. Yoshikawa Y., et al. Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. J. Pharm. Pharmacol. 49 (1997) 661-668
40. Guo J., et al. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv. 12 (2005) 35-39
41. Aliabadi H.M., et al. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release 104 (2005) 301-311
42. Yoshikawa H., and Seebach S. Lymphotropic delivery of cyclosporin A by intramuscular injection of biodegradable microspheres in mice. Biol. Pharm. Bull. 19 (1996) 1527-1529
43. Li Y., et al. In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres. Int. J. Pharm. 295 (2005) 67-76
44. Mitruka S.N., et al. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 115 (1998) 28-36
45. Iacono A.T., et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am. J. Respir. Crit. Care Med. 155 (1997) 1690-1698
46. Iacono A.T., et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Eng. J. Med. 354 (2006) 141-150
47. Burkart G.J., et al. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm. Res. 20 (2003) 252-256
48. Letsou G.V., et al. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 68 (1999) 2044-2048
49. Black K.S., et al. Site-specific suppression of cell-mediated immunity by cyclosporine. J. Invest. Dermatol. 94 (1990) 644-648
50. Bos J.D., and Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9 (2000) 165-169
51. Lopes L.B., et al. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm. 60 (2005) 25-30
52. Guo J., et al. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int. J. Pharm. 194 (2000) 201-207
53. Wang S., et al. Transdermal delivery of cyclosporin-A using electroporation. J. Control. Release 50 (1998) 61-70
54. Boinpally R.R., et al. Iontophoresis of lecithin vesicles of cyclosporin A. Int. J. Pharm. 274 (2004) 185-190
55. Santoianni P., et al. Intradermal drug delivery by low-frequency sonophoresis (25 kHz). Dermatol. Online J. 10 (2004) 24
56. Rothbard J.B., et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6 (2000) 1253-1257
57. Burns M.K., et al. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. Arch. Dermatol. 128 (1992) 786-790
58. Kaswan R.L. Intraocular penetration of topically applied cyclosporine. Transplant. Proc. 20 (1988) 650-655
59. Newton C., et al. Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 29 (1988) 208-215
60. Tang-Liu D.D., et al. Effects of four penetration enhancers on corneal permeability of drugs in vitro. J. Pharm. Sci. 83 (1994) 85-90
61. Furrer P., et al. Ocular tolerance of preservatives on the murine cornea. Eur. J. Pharm. Biopharm. 47 (1999) 105-112
62. Kuwano M., et al. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm. Res. 19 (2002) 108-111
63. Ding, S. et al. Allergan, Inc. Nonirritating emulsions for sensitive tissue, USP5474979
64. Acheampong A.A., et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr. Eye Res. 18 (1999) 91-103
65. Sall K., et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107 (2000) 631-639
66. Abdulrazik M., et al. Ocular delivery of cyclosporine A. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. S. T. P. Pharma. Sci. 11 (2001) 427-432
67. Calvo P., et al. Study of the mechanism of interaction of poly(ε-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int. J. Pharm. 103 (1994) 283-291
68. Juberias J.R., et al. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr. Eye Res. 17 (2002) 39-46
69. De Campos A.M., et al. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224 (2001) 159-168
70. Harper C.A., et al. Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int. Ophthalmol. 17 (1993) 337-340
71. Apel A., et al. A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Curr. Eye Res. 14 (1995) 659-667
72. Xie L., et al. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea 20 (2001) 748-752
73. Jaffe G.J., et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 105 (1998) 46-56